Lymphocyte to C-reactive protein ratio as a novel inflammatory biomarker: Validation and clinical relevance as an independent prognostic factor in cholangiocarcinoma

Table 4 Univariate and multivariate analyses of predictors of overall survival

Variables	Median OS	Univariate			Multivariate
		HR	95%CI	P value	HR	95%CI	P value
Age
≤ 70/> 70	21.86/17.03	0.919	0.489-1.728	0.793
Sex
Male/female	22.80/17.03	0.799	0.447-1.359	0.379
Obstructive jaundice
Yes/no	16.47/22.70	1.129	0.635-2.010	0.679
CEA
Abnormal/normal	21.86/22.80	1.02	0.575-1.811	0.946
CA199
Abnormal/normal	17.33/28.90	1.434	0.774-2.658	0.252
CA125
Abnormal/normal	19.43/22.80	1.118	0.593-2.108	0.729
CRP
Abnormal/normal	11.73/39.93	1.695	0.962-2.987	0.068
WBC count (109/L)
Abnormal/normal	19.43/22.80	1.09	0.626-1.899	0.760
Albumin (g/L)
Abnormal/normal	10.03/22.70	1.104	0.577-2.111	0.766
Hemoglobin (g/L)
Abnormal/normal	19.43/22.70	1.2	0.675-2.133	0.535
Tumor location
Extrahepatic/intrahepatic	25.53/19.43	0.787	0.551-1.125	0.189
Number of tumors
≥ 2/1	19.43/22.80	1.552	0.555-4.339	0.402
Tumor size
Largest diameter ≥ 5 cm/< 5 cm	8.27/22.80	1.528	0.813-2.873	0.188
Surrounding vascular invasion
Yes/no	7.37/24.87	2.07	1.130-3.793	0.019	1.292	0.629-2.655	0.486
Surrounding tissues invasion
Yes/no	19.10/32.03	1.565	0.667-3.674	0.304
Lymph node metastasis
Yes/no	17.03/24.87	1.605	0.913-2.820	0.100
Tumor stage
III/II	13.93/32.03	1.728	0.992-3.008	0.053	2.017	1.051-3.871	0.035
Tumor grade
III/II/I	15.70/22.70/46.51	1.497	1.003-2.234	0.094
R0 resection
No/ yes	7.37/24.87	2.156	1.042-4.461	0.038	3.547	1.567-8.029	0.002
LCR
Low/high	14.93/46.67	2.025	1.159-3.539	0.022	3.204	1.546-6.643	0.002
Complication
Yes/no	17.03/21.86	1.406	0.563-1.941	0.024	1.261	0.663-2.395	0.480
Postoperative adjuvant therapy
Yes/no	22.80/15.40	0.721	0.405-1.284	0.267

OS: Overall survival; HR: Hazard ratio; CI: Confidence interval; CEA: Carcinoembryonic antigen; CA: Carbohydrate antigen; CRP: C-reactive protein; WBC: White blood cell; LCR: Lymphocyte to C-reactive protein ratio.